证券代码：688677 证券简称：海泰新光 公告编号：2025-031 青岛海泰新光科技股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 5 月 15 日 （四） 表决方式是否符合《公司法》及公司章程的规定，大会主持情况等。 本次股东大会由公司董事会召集，以现场投票和网络投票相结合的方式进行 表决，由董事长郑安民先生主持。本次会议的召集、召开程序符合《中华人民共 和国公司法》、《中华人民共和国证券法》和《 海泰新光科技股份有限公司章程》 的规定。 （五） 公司董事、监事和董事会秘书的出席情况 1、 公司在任董事7人，出席7人； 2、 公司在任监事3人，出席3人； 3、 董事会秘书汪方华出席了本次股东大会。 二、 议案审议情况 （二） 股东大会召开的地点：青岛市崂山区科苑纬四路 100 号公司会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 ...

Core Viewpoint - The company, Qingdao Haitai Newlight Technology Co., Ltd., has announced the cancellation of 737,000 shares, which represents 0.6110% of the total share capital prior to cancellation, following a decision to change the purpose of repurchased shares from employee stock ownership plans to cancellation and capital reduction [1][2][3]. Group 1: Share Repurchase and Cancellation - The company will cancel 737,000 shares from its repurchase account, reducing the total share capital from 120,614,000 shares to 119,877,000 shares [1][5]. - The cancellation date for the repurchased shares is set for May 13, 2025 [4]. - The repurchase was initially intended for employee stock ownership plans or equity incentives, but the purpose has been changed to cancellation and capital reduction [2][3]. Group 2: Approval and Notification Process - The decision to change the purpose of the repurchased shares and to cancel them was approved at the company's general meeting in March 2025 [2][3]. - The company has complied with legal requirements by notifying creditors about the cancellation and has not received any claims for debt repayment within the stipulated period [3][6]. Group 3: Impact on Company Structure - After the cancellation, the company's total share capital will be 119,877,000 shares, with the shareholding structure remaining compliant with listing requirements [5][6]. - The cancellation is expected to enhance investor confidence and will not significantly impact the company's financial status, operational results, or debt repayment capabilities [6].

股票代码：688677 股票简称：海泰新光 公告编号：2025-029 青岛海泰新光科技股份有限公司 关于实施回购股份注销暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司本次将注销回购专用证券账户中的 737,000 股股份，占注销前公司 总股本 120,614,000 股的比例为 0.6110% 。本次注销完成后，公司总股本将由 120,614,000 股减少为 119,877,000 股，注册资本将由 120,614,000 元减少为 119,877,000 元。 回购股份注销日期：2025 年 5 月 13 日。 青岛海泰新光科技股份有限公司（以下简称"公司"）分别于 2025 年 3 月 3 日、2025 年 3 月 25 日召开第四届董事会第三次会议和 2025 年第一次临时股 东大会，审议通过了《关于变更部分回购股份用途并注销暨减少注册资本的议 案》，同意对回购公司股份的用途进行调整，本次回购股份用途由"用于实施 员工持股计划或股权激励"变更为"用于注销并相应减少注册资本" ...

青岛海泰新光科技股份有限公司 章 程 2025 年 3 月 中国·青岛 | | | | 第一章 | 总 则 1 | | --- | --- | | 第二章 | 经营宗旨和范围 2 | | 第三章 | 股份 2 | | 第四章 | 股东和股东大会 6 | | 第五章 | 董事会 23 | | 第六章 | 总经理及其他高级管理人员 35 | | 第七章 | 监事会 37 | | 第八章 | 财务会计制度、利润分配及审计 40 | | 第九章 | 通知和公告 45 | | 第十章 | 合并、分立、增资、减资、解散和清算 46 | | 第十一章 | 修改章程 49 | | 第十二章 | 附 则 49 | 青岛海泰新光科技股份有限公司 章 程 第一章 总 则 第一条 为维护青岛海泰新光科技股份有限公司、股东和债权人的合法权益， 规范公司的组织和行为，根据《中华人民共和国公司法》（以下简称"《公司法》"）《中 华人民共和国证券法》（以下简称"《证券法》"）、《中华人民共和国外商投资法》、《外 商投资企业设立及变更备案管理暂行办法》、《上海证券交易所科创板股票上市规则》、 《上市公司章程指引》和其他有关规定，制定本章程。 ...

证券代码：688677 证券简称：海泰新光 公告编号：2025-030 青岛海泰新光科技股份有限公司 关于变更公司注册资本、修订《公司章程》并办理工 商变更登记的公告 | 序号 | | 修改前 | | 修改后 | | --- | --- | --- | --- | --- | | 1 | 第六条 | 公司注册资本为人民币 | 第六条 | 公司注册资本为人民币 | | | 120,614,000 | 元 | 119,877,000 | 元 | | 2 | 第二十条 | 公司股份总数为 | 第二十条 | 公司股份总数为 | | | 120,614,000 | 股，全部为普通股。 | 119,877,000 | 股，全部为普通股。 | 除上述条款外，公司章程中的其他条款不变。 公司于 2025 年 3 月 26 日在上海证券交易所网站（www.sse.com.cn）和《中 国证券报》《上海证券报》《证券时报》披露了《关于注销公司部分回购股份并 减少注册资本暨通知债权人的公告》（公告编号：2025-013），自该公告披露之 日起 45 日内，公司未收到任何相关债权人要求公司清偿债务或提供相应担保的 通知。 变更事项最 ...

Investment Rating - The report maintains a "Recommendation" rating for the company, with a target price of 42 yuan [2][9]. Core Views - The company reported a revenue of 443 million yuan for 2024, a decrease of 5.90% year-on-year, and a net profit attributable to shareholders of 135 million yuan, down 7.11% [2][4]. - In Q4 2024, the company experienced a revenue increase of 31.59% to 124 million yuan and a net profit increase of 37.92% to 38 million yuan, indicating a potential upward turning point in performance [2][4]. - The company plans to distribute a cash dividend of 0.6 yuan per share (before tax) to all shareholders [2]. Financial Summary - Total revenue is projected to grow from 443 million yuan in 2024 to 828 million yuan by 2027, with a compound annual growth rate (CAGR) of 21.3% [4]. - Net profit is expected to increase from 136 million yuan in 2024 to 281 million yuan in 2027, reflecting a CAGR of 23.1% [4]. - Earnings per share (EPS) are forecasted to rise from 1.12 yuan in 2024 to 2.34 yuan in 2027, with corresponding price-to-earnings (P/E) ratios decreasing from 31 to 15 [4][9]. Business Performance - The company's medical endoscope business generated 345 million yuan in revenue for 2024, a decline of 7.04%, while optical revenue was 95 million yuan, down 1.80% [9]. - The company has seen a recovery in revenue growth in Q4 2024 and Q1 2025, attributed to reduced inventory levels among overseas clients and increasing demand [9]. - The company has completed certifications for its overseas subsidiaries, which mitigates trade friction risks and allows for smoother order fulfillment in the U.S. market [9]. Product Development - The company has launched a full range of laparoscopic products in the domestic market and has developed new endoscope products for various medical fields, which are now registered and available for sale [9]. - New products for the U.S. market, including a 4mm hysteroscope, have entered mass production, with further collaborations on next-generation systems with U.S. clients [9].

Core Viewpoint - The company reported a decline in revenue and net profit for 2024, but showed signs of recovery in Q4 2024 and Q1 2025, with a positive outlook for future earnings growth driven by inventory reduction among overseas clients and new product launches [1][2][4]. Financial Performance - For the full year 2024, the company achieved revenue of 443 million yuan (down 5.90%) and a net profit attributable to shareholders of 135 million yuan (down 7.11%) [1] - In Q4 2024, revenue was 124 million yuan (up 31.59%) and net profit attributable to shareholders was 38 million yuan (up 37.92%) [1] - For Q1 2025, revenue reached 147 million yuan (up 24.86%) and net profit attributable to shareholders was 47 million yuan (up 21.45%) [1] Product and Market Development - The company’s medical endoscope business generated revenue of 345 million yuan in 2024 (down 7.04%), while optical revenue was 95 million yuan (down 1.80%) [2] - International revenue for 2024 was 306 million yuan (down 6.5%), and domestic revenue was 135 million yuan (down 4.70%) [2] - The company has successfully launched a full range of laparoscopes and various endoscope products in the domestic market, and new products for the U.S. market are set to enter mass production [3] Future Outlook - The company expects net profits attributable to shareholders for 2025-2027 to be 180 million, 230 million, and 280 million yuan, representing year-on-year growth of 34.8%, 25.4%, and 23.1% respectively [4] - The estimated EPS for the same period is projected to be 1.51, 1.90, and 2.34 yuan, with corresponding PE ratios of 23, 19, and 15 times [4] - A target price of approximately 42 yuan is set for 2025, based on a valuation of 28 times [4]

公司研究 证 券 研 究 报 告 海泰新光（688677）2024 年报及 2025 年一季报点评 推荐（维持） 业绩拐点向上，海外子公司完成认证 目标价：42 元 事项： ❖ 公司发布 24 年年报及 25 年一季报，24 年全年营收 4.43 亿元（-5.90%），归母 净利润 1.35 亿元（-7.11%），扣非归母净利润 1.29 亿元（-5.26%）。24Q4，营 收 1.24 亿元（+31.59%），归母净利润 0.38 亿元（+37.92%），扣非归母净利润 0.40 亿元（+57.44%）。25Q1，营收 1.47 亿元（+24.86%），归母净利润 0.47 亿 元（+21.45%），扣非归母净利润 0.46 亿元（+26.89%）。公司拟向全体股东每 股派发现金红利 0.6 元（含税）。 评论： [ReportFinancialIndex] 主要财务指标 | | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | | 营业总收入(百万) | 443 | 558 | 682 | 828 | | 同比增速(%) | - ...

Group 1: Company Insights on Haitai New Light - Haitai New Light's endoscope repair business grew by 14% year-on-year in Q1 2024, with major customer demand increasing by over 25% [1] - The company is progressing with production line construction in the US and Thailand, with the US subsidiary expected to be certified by July 2024 and the Thailand subsidiary completed by the end of 2024 [1] - The company plans to establish a national marketing team of over 50 experienced members in 2024, with a focus on transitioning to complete machine sales [1] - The optical business is expected to see a slight decline in 2024, while the medical optical business is projected to grow by 23% in 2024 and 71% in Q1 2025 [1] - The company maintains a gross margin above 60%, with a good product yield rate of over 98% for complete machine products [1] Group 2: Company Insights on Zhou Dashing - Investors engaged in discussions regarding the 2024 annual report and Q1 2025 financial indicators, brand matrix, product structure, and terminal sales during a conference call [2] - The company ensured compliance with information disclosure regulations, maintaining the accuracy and completeness of disclosed information [2] Group 3: Institutional Overview of Hongshang Asset - Hongshang Asset was established in October 2013, created by a team from public funds and Sequoia Capital, serving as Sequoia's only equity securities asset management platform in China [3] - The company focuses on absolute return equity investment strategies, driven by fundamental research, and has received multiple industry awards for its performance [3] - The investment research team includes experienced professionals from large fund companies and top analysts, ensuring robust management and industry influence [3]

青岛海泰新光科技股份有限公司 2024 年年度股东大会会议资料 证券代码：688677 证券简称：海泰新光 青岛海泰新光科技股份有限公司 2024 年年度股东大会会议资料 2025 年 5 月 1 青岛海泰新光科技股份有限公司 2024 年年度股东大会会议资料 目录 | 青岛海泰新光科技股份有限公司 2024 年年度股东大会会议须知 | | 1 | | --- | --- | --- | | 青岛海泰新光科技股份有限公司 2024 年年度股东大会会议议程 | | 3 | | 议案一 《青岛海泰新光科技股份有限公司 2024 年年度报告全文及其摘要》 | | 5 | | 议案二 《青岛海泰新光科技股份有限公司 2024 年度董事会工作报告》 | | 6 | | 议案三 《青岛海泰新光科技股份有限公司 2024 年度监事会工作报告》 | | 7 | | 议案四 《青岛海泰新光科技股份有限公司 2024 年度财务决算报告》 | | 8 | | 议案五 《青岛海泰新光科技股份有限公司 2024 年度利润分配方案》 | | 9 | | 议案六 2025 年度独立董事津贴的议案》 | 《关于 | 10 | | 议案七 2 ...